Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Ovarian Cancer, Version 2.2013 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Morgan, R. J., Alvarez, R. D., Armstrong, D. K., Burger, R. A., Chen, L., Copeland, L., Crispens, M. A., Gershenson, D. M., Gray, H. J., Hakam, A., Havrilesky, L. J., Johnston, C., Lele, S., Martin, L., Matulonis, U. A., O'Malley, D. M., Penson, R. T., Powell, M. A., Remmenga, S. W., Sabbatini, P., Santoso, J. T., Schink, J. C., Teng, N., Werner, T. L., Dwyer, M. A., Hughes, M. 2013; 11 (10): 1199-1209

Abstract

These NCCN Guidelines Insights focus on the major updates to the 2013 NCCN Guidelines for Ovarian Cancer. Four updates were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials. The topics include 1) intraperitoneal chemotherapy, 2) CA-125 monitoring for ovarian cancer recurrence, 3) surveillance recommendations for less common ovarian histopathologies, and 4) recent changes in therapy for recurrent epithelial ovarian cancer. These NCCN Guidelines Insights also discuss why some recommendations were not made.

View details for Web of Science ID 000325929600004